If you've researched GLP-1 medications, you've probably noticed something confusing: Ozempic and Wegovy both contain semaglutide, both are made by Novo Nordisk, both are weekly injections, yet they're marketed as different drugs with different prices and different prescribing rules. What gives?
The answer matters because choosing between them (or being prescribed one over the other) affects your eligibility, your insurance coverage, and your out-of-pocket cost. Here's a clear breakdown.
The Short Answer
Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. Both contain the same active ingredient (semaglutide) at different maximum doses, packaged in different pens, with different official indications.
From a pharmacological standpoint, they are the same molecule. From a regulatory and insurance standpoint, they are different products.
The Key Differences
*FDA Indication:*
*Maximum Dose:*
*Approval Year:*
*Pricing (2026, brand-name list price):*
*Insurance Coverage:*
Why Doctors Prescribe Ozempic Off-Label for Weight Loss
Because Ozempic and Wegovy are pharmacologically nearly identical, many physicians prescribe Ozempic off-label for weight loss, particularly when a patient's insurance covers Ozempic but not Wegovy. This is legal and clinically reasonable, though it has contributed to the well-documented Ozempic shortages of recent years.
The trade-off: Ozempic's max dose (2.0mg) is slightly lower than Wegovy's (2.4mg), so patients who need the higher therapeutic dose for weight management may not reach their goal weight as efficiently.
What the Clinical Trials Show
STEP-1 (NEJM, 2021), the foundational trial for Wegovy, showed average weight loss of approximately 14.9% of body weight at 68 weeks with semaglutide 2.4mg in non-diabetic adults with overweight or obesity.
SUSTAIN trials for Ozempic in type 2 diabetes patients showed average weight loss of approximately 6–10% at lower doses, though weight loss was a secondary endpoint.
SELECT trial (NEJM, 2023) showed semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in patients with overweight/obesity and established CVD over a mean ~40-month follow-up.
Results may vary.
Compounded Semaglutide: The Third Option
When the FDA places semaglutide on its drug shortage list, state-licensed compounding pharmacies may legally prepare semaglutide formulations. Compounded semaglutide:
For patients without insurance coverage for brand-name semaglutide, compounded semaglutide is often the most accessible option.
Which One Is Right for You?
*Choose Ozempic if:*
*Choose Wegovy if:*
*Consider compounded semaglutide if:*
What Majesta Health Offers
At Majesta Health, we provide compounded semaglutide through licensed, FDA-registered 503A compounding pharmacies, with board-certified physician oversight. Take our free 2-minute assessment at /quiz to see if you qualify.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Individual results may vary.